Skip to main content
OpenTrials
Completed

NCT Number: NCT05162989

iCare HOME2 Clinical Trial

The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

East West Eye Institute

Los Angeles, California, 90013, United States

About this study

The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position.

The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or
  • Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion criteria

  • Active ocular infection (e.g., pink eye or infectious conjunctivitis)
  • Recent trauma to the eye including corneal laceration or corneal/scleral perforation
  • Disabling arthritis or difficulty handling the tonometer
  • Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm)
  • Involuntary, rapid, and repetitive eye movements (nystagmus)
  • Low uncorrected near visual acuity of 20/200 or below
  • Significant glaucomatous central field loss
  • Only one functional eye
  • Poor or off-center visual fixation
  • Poor hearing and/or communicates using sign language
  • Keratoconus (or other corneal disorder)
  • Congenitally small eye (microphthalmos)
  • Enlarged eyeball from the childhood glaucoma (buphthalmos)
  • Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials
  • Any affiliation with Icare and its employees
  • High corneal astigmatism (>3d)
  • History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile)
  • Corneal scarring
  • Very thick or very thin corneas (central corneal thickness greater than 600 μm or less than 500 μm)
  • Cataract extraction within the last 2 months
  • Wearing contact lenses during the study

Treatment and study plan

iCare HOME2 vs iCare IC200

Device

Measurement of IOP with iCare HOME2 compared with iCare IC200.

Primary outcomes

  1. Repeatability of IOP measurements

    Time frame: Through study completion, an average of 1-2 months

    Repeatability of IOP measurements comparison of iCare HOME2 vs iCare IC200

Sponsors and collaborators

Lead sponsor

Icare Finland Oy

Industry

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 20, 2021
Registry last updated
Dec 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.